



Compound ID: 51

EW53902-30-P1A CDCl3 ZKNJ\_018\_400MHz



Acquisition Time (sec) 3.0002  
Comment EW53902-30-P1A CDCl3 ZKNJ\_018\_400MHz  
Date 04 Mar 2024 03:00:42 (GMT)  
Frequency (MHz) 399.9340  
Nucleus 1H  
Number of Transients 8  
Origin QUANTUM M-1  
Original Points Count 24038  
Owner admin  
Points Count 65536  
Pulse Sequence s1pul30  
Receiver Gain 70.28  
SW(cyclical) (Hz) 8012.00  
Solvent CHLOROFORM-d  
Spectrum Offset (Hz) 2399.6038  
Spectrum Type undefined  
Sweep Width (Hz) 8011.88  
Temperature (degree C) 25.550

Confidential. For research information only




Operator:

Date:


# LCMS REPORT

---

Compound ID : 51  
 Sample ID : EW53902-30-P1B  
 Injection Vol : 3ul  
 Location : vial34  
 Tray Name : 2  
 Acq Method : D:\method\5-95AB\_3min\_220&254.lcm  
 Org DataFile : D:\DATA\2024\2403\240304\EW53902-30-P1B.lcd  
 Injection Date : 3/4/2024 11:26:47  
 Instrument : LCMS-070



- 1 PDA Multi 1 / 220nm,4nm
- 2 PDA Multi 2 / 254nm,4nm



=====  
 Integration Result  
 =====

Peak Table

PDA Ch1 220nm

Peak#	Ret. Time	Height	Height%	USP Width	Area	Area%
1	1.339	1529746	100.000	0.037	2235521	100.000

Peak Table


PDA Ch2 254nm

Peak#	Ret. Time	Height	Height%	USP Width	Area	Area%
1	1.339	1739577	100.000	0.038	2582084	100.000

Operator: \_\_\_\_\_


Date: \_\_\_\_\_

Mass Spectrum  
RefTime: 1.343 Datafile: D:\DATA\2024\2403\240304\EW53902-30-PIB.lcd



# HPLC REPORT

Compound ID : 51  
 Sample ID : EW53902-30-P1D  
 Vial# : 27  
 Injection Volumn : 3  
 Filename : D:\DATA\2024\2403\240304\EW53902-30-P1D.lcd  
 Method Name : D:\method\10-80AB\_3min.lcm  
 Instrument : HPLC-087  
 Run time : 03/04/2024 10:22:13



## Integration result

PeakTable


Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	1.499	0.026	0.000	2529	3106	0.080
2	1.561	0.024	2.467	1311	1267	0.033
3	1.714	0.029	5.822	9116	11295	0.292
4	1.755	0.027	1.435	5943	5716	0.148
5	1.816	0.026	2.300	3127796	3832109	99.062
6	2.430	0.023	25.097	1555	1496	0.039
7	2.513	0.030	3.126	6536	8508	0.220
8	2.552	0.031	1.297	3982	4895	0.127
Total				3158768	3868394	100.000

Operator : \_\_\_\_\_

Date : \_\_\_\_\_

# HPLC REPORT

Compound ID : 51  
 Sample ID : EW53902-30-P1D  
 Filename : D:\DATA\2024\2403\240304\EW53902-30-P1D.lcd  
 Method Name : D:\method\10-80AB\_3min.lcm  
 Instrument : HPLC-087  
 Run time : 03/04/2024 10:22:13



## Integration result

### PeakTable

PDA Ch2 254nm


Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	1.561	0.023	0.000	1421	1272	0.031
2	1.719	0.032	5.749	5338	6424	0.159
3	1.755	0.027	1.219	9355	9014	0.223
4	1.815	0.027	2.249	3048181	4029562	99.508
5	2.430	0.024	24.239	2005	1940	0.048
6	2.552	0.025	5.031	1138	1267	0.031
Total				3067439	4049480	100.000

Operator : \_\_\_\_\_

Date : \_\_\_\_\_

# HPLC REPORT

Compound ID : 51  
 Sample ID : EW53902-30-P1D  
 Filename : D:\DATA\2024\2403\240304\EW53902-30-P1D.lcd  
 Method Name : D:\method\10-80AB\_3min.lcm  
 Instrument & Column : HPLC-087  
 Run time : 03/04/2024 10:22:13



1 PDA Multi 3 / 215nm,4nm

## Integration result

### PeakTable

PDA Ch3 215nm

Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	0.510	0.055	0.000	357	1060	0.029
2	1.499	0.026	24.421	2401	2935	0.081
3	1.714	0.028	7.981	7700	8845	0.245
4	1.755	0.025	1.537	5764	5304	0.147
5	1.815	0.025	2.408	3059282	3570172	99.006
6	2.429	0.021	26.900	1191	1064	0.030
7	2.512	0.029	3.337	7963	9930	0.275
8	2.552	0.034	1.268	4535	5338	0.148
9	2.756	0.033	6.067	957	1365	0.038
Total				3090150	3606013	100.000


Operator : \_\_\_\_\_

Date : \_\_\_\_\_

# Chiral SFC Report

Compound ID : 51  
 Sample ID : EW53902-30-P1A\_I1601  
 Injection Vol : 5ul  
 Location :Tray1 vial5  
 Acq Method : D:\METHODS\SIC-3-IPA+ACN(DEA)-20-60-3ML-35T.lcm  
 Raw Data : D:\DATA\2024\202403\20240304\EW53902-30-P1A\_I1601.lcd  
 Injection Date : 3/4/2024 4:54:14 PM  
 Instrument : CAS-WH-ANA-SFC-I(SHIMADZU LC-30ADsf)

Method details: "Column:Chiralpak IC-3 50\*4.6mm I.D.,3um  
 Mobile phase:Phase A for CO2,and Phase B for IPA+ACN(0.05%DEA);  
 Gradient elution: From 20% to 60% of IPA+ACN(0.05%DEA) in CO2 ,  
 Flow rate:3mL/min;Detector:PDA;  
 Column Temp:35C;Back Pressure:100Bar"



=====  
 Integration Result  
 =====

Peak Table

Peak#	Ret. Time	Height	Height%	Resolution(USP)	Area	Area%
1	1.153	33036	3.279	--	83232	3.273
2	1.277	974431	96.721	1.797	2459655	96.727



Operator: \_\_\_\_\_

Date: \_\_\_\_\_


# LCMS REPORT

---

Compound ID : 1  
 Sample ID : EW53902-29-P1A  
 Injection Vol : 3ul  
 Location : vial02  
 Tray Name : 2  
 Acq Method : D:\method\5-95CD\_1.5min\_220&254\_POS.lcm  
 Org DataFile : D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd  
 Injection Date : 02/29/2024 12:13:39  
 Instrument : LCMS-053 2-109



- 1 PDA Multi 1 / 220nm,4nm
- 2 PDA Multi 2 / 254nm,4nm




---

## Integration Result

---

### Peak Table

PDA Ch1 220nm						
Peak#	Ret. Time	Height	Height%	USP Width	Area	Area%
1	0.306	8241	0.613	0.051	18296	1.299
2	0.378	14750	1.097	0.024	14364	1.020
3	0.407	17695	1.316	0.059	15138	1.075
4	0.439	259802	19.317	0.022	298568	21.196
5	0.698	9760	0.726	0.026	9412	0.668
6	0.794	10436	0.776	0.060	28023	1.989
7	0.860	15102	1.123	0.000	36080	2.561
8	0.917	1001985	74.500	0.025	969333	68.814
9	1.016	7169	0.533	0.191	19422	1.379

### Peak Table

PDA Ch2 254nm


Peak#	Ret. Time	Height	Height%	USP Width	Area	Area%
1	0.272	7560	0.453	0.151	15931	0.809
2	0.301	10610	0.635	0.043	13142	0.668
3	0.335	9811	0.587	0.052	11046	0.561
4	0.379	27971	1.675	0.095	33984	1.726
5	0.407	49609	2.970	0.127	57820	2.937
6	0.439	365682	21.894	0.024	542425	27.553
7	0.698	16636	0.996	0.039	66536	3.380
8	0.771	12440	0.745	0.786	32800	1.666
9	0.793	18686	1.119	0.063	28184	1.432
10	0.860	19409	1.162	0.684	51490	2.616
11	0.917	1124282	67.312	0.025	1103405	56.049
12	1.017	7557	0.452	0.044	11887	0.604

Operator: \_\_\_\_\_


Date: \_\_\_\_\_

Mass Spectrum


RefTime: 0.303 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd




RefTime: 0.437 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd




RefTime: 0.795 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd




RefTime: 0.862 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd



RefTime: 0.920 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd



RefTime: 1.020 Datafile: D:\DATA\2024\2402\240229\EW53902-29-P1A.lcd



## Metabolite profiling in human liver microsomes for Cpd.51

<b>Test article</b>	Cpd.51
<b>Purpose</b>	To identify major metabolites of test compound in human liver microsomes
<b>Study director(s)</b>	Jinyu Ba
<b>Major contributor(s)</b>	Haihong Li
<b>Effective date</b>	December 24 <sup>th</sup> , 2025
<b>Sponsor</b>	烟台大学
<b>Study number</b>	CPB-P25-66382

### Corresponding address

Shanghai ChemPartner Co., Ltd.

2727 Jinke Rd, Block A, Pudong, Shanghai, 201203, China

To the best of our knowledge this report has been reviewed for completeness, accuracy, and compliance with the protocol.

**Study director:**

---

Date

Jinyu Ba, M.S.  
Study Director of Metabolite ID  
Shanghai ChemPartner Co., Ltd.  
Tel: (86) 21-51320088 Ext. 3073  
Email: [jyba@chempartner.com](mailto:jyba@chempartner.com)

**Reviewed and approved by:**

---

Date

Haihong Li, M.S.  
Senior Research Scientist of Metabolite ID  
Shanghai ChemPartner Co., Ltd.  
Tel: (86) 21-51320088 Ext. 3074  
Email: [hhl1@chempartner.com](mailto:hhl1@chempartner.com)

---

**CONTENTS**

<b>1. INTRODUCTION AND OBJECTIVE .....</b>	<b>4</b>
<b>2. MATERIALS AND REAGENTS .....</b>	<b>4</b>
<b>3. EXPERIMENTAL PROCEDURES .....</b>	<b>4</b>
<b>4. LC-UV-MS CONDITIONS .....</b>	<b>5</b>
<b>5. SUMMARY .....</b>	<b>5</b>
Figure 1. LC-UV ( $\lambda = 250-260$ nm) chromatograms of Cpd.51 and its metabolites incubated in human liver microsomes with or without NADPH for 0 min and 5 min .....	6
Figure 2. LC-MS EIC of Cpd.51 and its metabolites incubated in human liver microsomes with NADPH for 0 min and 5 min. ....	6
Figure 3. LC-MS EIC of M508 in T <sub>0</sub> , T <sub>5</sub> , T <sub>5-w/o</sub> and neat solution. ....	9
Figure 4. Proposed metabolic pathways of Cpd.51 incubated in human liver microsomes in the presence of NADPH .....	10
Table 1. Major metabolites of Cpd.51 incubated in human liver microsomes in the presence of NADPH .....	11
<b>6. RESULTS AND DISCUSSION .....</b>	<b>12</b>

## INTRODUCTION AND OBJECTIVE

The objective of this study is to identify major metabolites of Cpd.51 generated in human liver microsomes.

*In vitro* metabolites identification was conducted after incubating Cpd.51 (parent compound, final concentration 10  $\mu$ M) with human liver microsomes (final protein concentration, 1 mg/mL) at 37 °C in 100 mM potassium phosphate buffer containing 5 mM MgCl<sub>2</sub> in the presence of NADPH or without NADPH. The samples taken at 0 minute (min) and 5 min were quenched by methanol and analyzed using Waters G2-XS Q-ToF UPLC-MS system with positive-ion and negative-ion electrospray ionization. LC-MS extract ion chromatograms (EIC) of the T<sub>5</sub> and T<sub>0</sub> were compared to identify the major putative metabolites. The MS/MS spectra of Cpd.51 and the metabolites were obtained during positive-ion and negative-ion electrospray. The possible chemical structures of the metabolites were deduced based on their MS/MS spectra and retention times. The metabolic pathways of Cpd.51 in human liver microsomes were proposed.

## MATERIALS AND REAGENTS

Cpd.51 (Purity: 99.1%), provided by 烟台大学  
 Acetonitrile, SIGMA-ALDRICH (Cat. # 34851-4L, Lot. # WXBD3947V)  
 Methanol (MeOH), SIGMA-ALDRICH (Cat. # 34860-4L-R, Lot. # WXBD3647V)  
 K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, Titan (Lot. # P2128180)  
 KH<sub>2</sub>PO<sub>4</sub>, Titan (Lot. # P1343518)  
 MgCl<sub>2</sub>·6H<sub>2</sub>O, Titan (Lot. # P1040534)  
 Human liver microsomes (HLM), XENOTECH (Cat. # H0610, Lot. # 2110263)  
 NADPH, MCE (Cat. # HY-F0003, Lot. # 728189)

## EXPERIMENTAL PROCEDURES

1. Assay buffer: 100 mM potassium phosphate buffer (K<sup>+</sup>/Mg<sup>2+</sup> buffer, pH 7.4):

Reagent	K <sub>2</sub> HPO <sub>4</sub> ·3H <sub>2</sub> O (g)	KH <sub>2</sub> PO <sub>4</sub> (g)	MgCl <sub>2</sub> ·6H <sub>2</sub> O (g)	H <sub>2</sub> O (mL)
	FW: 228.22	FW: 136.09	FW: 203.3	
100 mM	9.240265	1.297376	0.509460	500

2. Preparation of cofactor solution in the K<sup>+</sup>/Mg<sup>2+</sup> Buffer:

Reagent	K <sup>+</sup> /Mg <sup>2+</sup> buffer (mL)	NADPH (mg)	Total (mL)
8 mM NADPH	1.049	7.00	1.049

3. Assay procedure:

- 1) T<sub>0</sub>: add 20  $\mu$ L of 20 mg/mL liver microsomes (LM) stock solution, 100  $\mu$ L of cofactor solution and 279  $\mu$ L of K<sup>+</sup>/Mg<sup>2+</sup> buffer to the T<sub>0</sub> vial, and quench the mixed solution by adding 1200  $\mu$ L of MeOH, vortex at 1000 rpm for 5 min, and then add 1  $\mu$ L of 4 mM compound solution.
- 2) T<sub>5</sub>: add 20  $\mu$ L of 20 mg/mL liver microsomes (LM) stock solution, 100  $\mu$ L of cofactor solution and 279  $\mu$ L of K<sup>+</sup>/Mg<sup>2+</sup> buffer to the T<sub>5</sub> vial, and then start the reaction by adding 1  $\mu$ L of 4 mM compound solution. After 5 min incubation, quench the reaction by adding 1200  $\mu$ L of MeOH and vortex at 1000 rpm for 5 min.
- 3) T<sub>5-w/o</sub>: add 20  $\mu$ L of 20 mg/mL liver microsomes (LM) stock solution and 379  $\mu$ L of K<sup>+</sup>/Mg<sup>2+</sup> buffer to the T<sub>5-w/o</sub> vial, and then start the reaction by adding 1  $\mu$ L of 4 mM compound solution. After 5 min incubation, quench the reaction by adding 1200  $\mu$ L of

MeOH and vortex at 1000 rpm for 5 min.

- 4) Protein precipitation: centrifuge quenched samples at 14000 rpm for 5 min.
- 5) 100  $\mu$ L of the supernatant was diluted with 50  $\mu$ L of water and the mixture was vortexed for 5 min, and centrifuged at 14000 rpm for 5 min. Then 10  $\mu$ L of the supernatant was injected onto LC-UV-MS for analysis.

## LC-UV-MS CONDITIONS

- 1) LC condition:

Column: Acquity UPLC<sup>®</sup>BEH C18 (2.1  $\times$  50 mm, 1.7  $\mu$ m);

Mobile Phase: A (H<sub>2</sub>O with 0.1% formic acid);  
B (ACN with 0.1% formic acid);

Gradient Program:

Time (min)	Flow Rate ( $\mu$ L/min)	A (%)	B (%)
0.00	400	98	2
0.34	400	98	2
2.00	400	80	20
7.00	400	30	70
11.00	400	5	95
12.00	400	5	95
12.10	400	98	2
13.00	400	98	2

- 2) MS condition:

UPLC-UV-G2-XS Q-TOF: MS<sup>E</sup> Centroid ESI (+/-)

<b>Scan Mode:</b> MS <sup>E</sup> Centroid
Source
Capillary (kV): 3.00 (+) / 2.50 (-)
Sampling Cone: 40
Source Offset: 80
Temperature ( $^{\circ}$ C)
Source: 120
Desolvation: 350
Gas Flows (L/h)
Cone Gas: 50
Desolvation Gas: 600

## SUMMARY


Cpd.51 was transformed into 10 major metabolites in this study, which were named as  $M_{E.M.}$  according to the exact mass of metabolites and the retention time in the current LC condition.

LC-UV chromatograms of Cpd.51 and its metabolites incubated in human liver microsomes are shown in **Figure 1**, while the LC-MS chromatograms are shown in **Figure 2**. Proposed metabolic pathways of Cpd.51 in human liver microsomes are shown in **Figure 4**. A summary, including observed  $m/z$  value, retention time, relative UV abundance, and MS peak area of Cpd.51 and its metabolites in human liver microsomes is presented in **Table 1**.

M508 was also detected in T<sub>0</sub>, T<sub>5-w/o</sub> and neat solution, while the LC-MS chromatograms are shown in **Figure 3**.


**Figure 1.** LC-UV ( $\lambda = 250-260$  nm) chromatograms of Cpd.51 and its metabolites incubated in human liver microsomes with or without NADPH for 0 min and 5 min


Cpd 51 HLM T5-w/o supernatant\_MeOH




**Figure 2.** LC-MS EIC of Cpd.51 and its metabolites incubated in human liver microsomes with NADPH for 0 min and 5 min.


Positive-ion mode:






Negative-ion mode:



**Figure 3.** LC-MS EIC of M508 in T<sub>0</sub>, T<sub>5</sub>, T<sub>5-w/o</sub> and neat solution.

**Figure 4.** Proposed metabolic pathways of Cpd.51 incubated in human liver microsomes in the presence of NADPH

**Table 1.** Major metabolites of Cpd.51 incubated in human liver microsomes in the presence of NADPH

Peak ID	Found <i>m/z</i>	Mass Shift	Biotransformation	R.T. (min)	Human liver microsome	
					Relative UV*	MS peak area
Parent (T <sub>0</sub> )	507.3223 [M+H] <sup>+</sup>	n/a	n/a	5.60	100.00%	1.19E+04
	505.3066 [M-H] <sup>-</sup>					1.59E+04
Parent (T <sub>5</sub> )	507.3223 [M+H] <sup>+</sup>	n/a	n/a	5.60	54.06%	6.69E+03
	505.3066 [M-H] <sup>-</sup>					8.97E+03
M504	505.3064 [M+H] <sup>+</sup>	-2.0157	Desaturation	5.91	1.09%	1.11E+02
	503.2909 [M-H] <sup>-</sup>					ND
M508	509.3382 [M+H] <sup>+</sup>	2.0156	Hydrogenation	5.32	11.61%	2.40E+03
	507.3222 [M-H] <sup>-</sup>					2.59E+03
M522a	523.3130 [M+H] <sup>+</sup>	15.9933	Hydroxylation	4.33	+	6.00E+01
	521.2999 [M-H] <sup>-</sup>					1.08E+02
M522b	523.3158 [M+H] <sup>+</sup>	15.9968	Hydroxylation	4.90	8.13%	7.86E+02
	521.3034 [M-H] <sup>-</sup>					9.78E+02
M524a	525.3320 [M+H] <sup>+</sup>	18.0100	Hydroxylation + Hydrogenation	3.96	+	3.90E+01
	523.3166 [M-H] <sup>-</sup>					5.00E+01
M524b	525.3320 [M+H] <sup>+</sup>	18.0064	Hydroxylation + Hydrogenation	4.29	+	1.00E+01
	523.3130 [M-H] <sup>-</sup>					1.20E+01
M524c	525.3319 [M+H] <sup>+</sup>	18.0089	Hydroxylation + Hydrogenation	5.09	+	5.90E+01
	523.3155 [M-H] <sup>-</sup>					1.00E+02
M537	538.3284 [M+H] <sup>+</sup>	31.0069	+ NHO	4.85	+	5.50E+01
	536.3135 [M-H] <sup>-</sup>					4.30E+01
M538	539.3121 [M+H] <sup>+</sup>	31.9907	2 × Hydroxylation	3.49	0.69%	2.50E+01
	537.2973 [M-H] <sup>-</sup>					4.10E+01
M1012	1013.6331 [M+H] <sup>+</sup>	506.3124	Dimer	7.83	5.16%	7.87E+02
	1011.6190 [M-H] <sup>-</sup>					8.54E+02

\*: All percentages were calculated based on the detected UV ( $\lambda = 250-260$  nm) absorption relative to that of parent in T<sub>0</sub> sample (normalized as 100%);

+: Only detected in MS;


n/a: Not applicable.

## RESULTS AND DISCUSSION


### Structure elucidation of Cpd.51 and its metabolites


#### 1) MS fragmentation assignment of Cpd.51

MSMS spectrum was obtained for Cpd.51 and the fragments were assigned to facilitate structure elucidation of Cpd.51 metabolites.




Cpd 51 MEOH:H2O=1:1  
139 763 (5.608) Cm (761:765)






Cpd 51 MEOH:H2O=1:1 neg  
148 508 (5.604) Cm (507:509)




## 2) M504 (Desaturation)




Cpd 51 HLM T10 supernatant\_MeOH

141 536 (5.903) Cm (535:538-(519:528+552:558))





## 3) M508 (Hydrogenation)



Cpd 51 HLM T10 supernatant\_MeOH


141 483 (5.320) Cm (483:485)






Cpd 51 HLM T10 supernatant\_MeOH neg

151 152 (5.344) Cm (152:153)





4) M522a (Hydroxylation)



Cpd 51 HLM T5 supernatant\_MeOH LM=12.0


147 490 (4.332) Cm (487:493)






Cpd 51 HLM T5 supernatant\_MeOH LM=12.0

152 490 (4.332) Cm (490:493-(482:487+497:500))





5) M522b (Hydroxylation)



Cpd 51 HLM T5 supernatant\_MeOH LM=12.0

147 555 (4.902) Cm (554:557-(536:549+564:577))







Cpd 51 HLM T5 supernatant\_MeOH LM=12.0

152 555 (4.902) Cm (553:557-(539:550+566:575))

1: TOF MSMS 521.30ES-  
1.76e3





6) M524a (Hydroxylation + Hydrogenation)



Cpd 51 HLM T10\_MeOH/H2O=1/3


146 225 (3.975) Cm (225)






Cpd 51 HLM T10\_MeOH/H2O=1/3 neg

153 226 (3.992) Cm (225:226-212:221)





## 7) M524b (Hydroxylation + Hydrogenation)



Cpd 51 HLM T10\_MeOH/H2O=1/3


146 243 (4.298) Cm (242:243)






Cpd 51 HLM T10\_MeOH/H2O=1/3  
150 243 (4.290) Cm (243:244)

1: TOF MSMS 523.32ES-  
523.3130 2.26e3  
[M-H]<sup>-</sup>





## 8) M524c (Hydroxylation + Hydrogenation)




Cpd 51 HLM T10 \_MeOH/H2O=1/3

146 289 (5.097) Cm (289:290)






Cpd 51 HLM T10\_MeOH/H2O=1/3 neg  
 153 289 (5.106) Cm (288:289-299:306)





9) M537 (+ NHO)




Cpd 51 HLM T10 \_MeOH/H2O=1/3

144 275 (4.860) Cm (274:276)






Cpd 51 HLM T10\_MeOH/H2O=1/3  
150 275 (4.860) Cm (275)




## 10) M538 (2 × Hydroxylation)




Cpd 51 HLM T10 supernatant\_MeOH neg

149.99 (3.499) Cm (99-(93:97+106:108))

3: TOF MSMS 537.30ES-  
537.2973 454



11) M1012 (Dimer)



Cpd 51 HLM T10 supernatant\_MeOH

143 296 (7.825) Cm (296:297)

2: TOF MSMS 1013.68ES+



Cpd 51 HLM T10 supernatant\_MeOH neg

151 222 (7.834) Cm (222)

4: TOF MSMS 1011.62ES-  
3.77e4

